Full Press Release Details
Harrow Health Raises
Approximately $11 Million in Sale of Series B Preferred Stock
NASHVILLE, Tenn., May 5,
2021 - Harrow Health, Inc. (NASDAQ: HROW) ("Harrow Health" or the "Company"), an ophthalmic-focused healthcare
company, today announced that the Company has closed on a private sale to B. Riley Securities, Inc. of 440,000 shares of its newly created
Series B Cumulative Preferred Stock (the "Preferred Stock") for net proceeds of approximately $10.67 million.
to use the net proceeds from this transaction for general corporate purposes, including funding future strategic product acquisitions
and related investments, making capital expenditures and funding working capital.
transaction, Mark L. Baum, Harrow Health's Chief Executive Officer, said, "We are pleased to have closed on this $11
million Series B Preferred Stock transaction, which, coupled with our recently closed $55 million unsecured senior notes offering
and the $10 million in proceeds from our sale of Eton Pharmaceuticals stock, brings total funds raised by the Company in 2021
to just over $75 million. We expect this increase in our overall cash position to provide ample funds to aggressively pursue several
current business development engagements to acquire, partner or in-license FDA-approved or late-stage FDA-approvable ophthalmic
drug candidates currently under negotiation. We are very appreciative of the support from the financial community and our stockholders
in Harrow Health's vision, and we are very excited about the transformative opportunities we see in the near future."
shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Preferred Stock
in any state or jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
(NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns ImprimisRx, the nation's leading ophthalmology
outsourcing and pharmaceutical compounding business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic
eye disease. Harrow Health also holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals,
all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical stage drug candidates
being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors
section of the corporate website, harrowinc.com.
HROW Raises Approximately
$11 Million in Sale of Series B Preferred Stock
contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be considered such "forward-looking statements."
Such forward looking statements include, but are not limited to, statements regarding the intended use of proceeds. Because these
forward-looking statements involve known and unknown risks and uncertainties, there are important factors that could cause actual
results, events or developments to differ materially from those expressed or implied by these forward-looking statements. Additional
risks and uncertainties are more fully described in Harrow Health's filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended December 31, 2020. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only
as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking
statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated
Jamie Webb, Director
of Communications and Investor Relations